| Literature DB >> 35619905 |
Zhuo Liu1, Liyuan Ge1, Lei Liu1, Xun Zhao1, Kewei Chen1, Yuxuan Li1, Abudureyimujiang Aili2, Min Lu3, Xinlong Pei4, Dengyang Han5, Shudong Zhang1, Lulin Ma1.
Abstract
Background: This study aims to report the surgical management, complications, and outcomes for patients with retroperitoneal tumor and venous thrombus.Entities:
Keywords: clinical experience; postoperative outcome; retroperitoneal tumor; surgery strategy; tumor thrombus
Year: 2022 PMID: 35619905 PMCID: PMC9128060 DOI: 10.3389/fonc.2022.873729
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Typical imaging manifestations and schematic diagram of PUTH-RT grading system for adrenal gland with venous thrombosis.
PUTH-RT grading system of adrenal tumor thrombus with vein based on surgical technique.
| Classification Abbreviation | Graded Full Name | Description | Case Load | Description of Surgical Technique |
|---|---|---|---|---|
| PUTH-RT-1a | Adrenal PUTH-RT 1a grade tumor thrombus | Cancer thrombus is confined to the central adrenal vein. | 2 | Hem-o-lok was used to clamp or cut off the central adrenal vein. |
| PUTH-RT-1b | Adrenal PUTH-RT 1b grade tumor thrombus | The tumor thrombus entered the left renal vein along the left central adrenal vein but did not enter the inferior vena cava. | 2 | During the operation, the inferior vena cava was partially blocked by side-wall forceps, and the left renal vein was incised during the operation. After taking out the tumor thrombus, the left renal vein was sutured. If tumor thrombus invades the wall of left renal vein, then Hem-o-lok clamp or straight-line cutter should be used to cut off the left renal vein. |
| PUTH-RT-2 | Adrenal PUTH-RT grade 2 tumor thrombus | The tumor thrombus invades the inferior vena cava, and its proximal end is located under the liver. | 6 | If the distal end of the tumor thrombus is located above the level of renal vein, then the vena cava of the distal end of the tumor thrombus is blocked by the vascular blocking tape in turn, and the inferior vena cava is cut after the tumor thrombus is close to the vena cava. If the distal end of the tumor thrombus is below the level of renal vein, vascular occlusion needs to block the blood reflux of the healthy renal vein at the same time. |
| PUTH-RT-3 | Adrenal PUTH-RT grade 3 tumor thrombus | The tumor thrombus invades the inferior vena cava, and its proximal end is located behind the liver. | 6 | During the operation, the liver ligament was severed, the inferior vena cava behind the liver was exposed and dissociated, and the first hepatic portal was dissociated by Pringer method. The distal vena cava, the first hepatic portal vein, the contralateral renal vein, and the proximal vena cava of the tumor thrombus were blocked, in turn, by the vascular blocking band, and then, the inferior vena cava was cut to remove the thrombus. |
| PUTH-RT-4 | Adrenal PUTH-RT grade 4 tumor thrombus | The tumor thrombus invaded the inferior vena cava and reached above the diaphragm. | 3 | You can cut the diaphragm central tendon around the vena cava or cut the diaphragm directly, gently push, and squeeze the tumor thrombus into the inferior vena cava, so that the tumor thrombus changes from above the diaphragm to below the diaphragm and then take out the tumor thrombus; conventional methods need to open the chest to establish cardiopulmonary bypass and open the right atrium to remove thrombus under the condition of hypothermic cardiac arrest or non-cardiac arrest. |
Baseline characteristics of all 19 patients.
| Characteristics | Result |
|---|---|
| Age (years), median | 42 (16–69) |
| Gender, male/female | 7/12 |
| BMI (kg/m2), median | 24.1 (18.3–36.2) |
| Side, n | |
| Left | 6 |
| Right | 13 |
| Tumor size (cm), median | 9.1 (2.8–18.3) |
| Clinical N stage, n | |
| cN0 | 13 |
| cN1 | 6 |
| Clinical M stage, n | |
| cM0 | 13 |
| cM1 | 6 |
| IVC thrombus length (cm), mean (SD) | 4.0 (1.0–12.3) |
| Clinical symptoms, n | 8 |
| No | 8 |
| Local symptoms | 3 |
| Systemic symptoms |
BMI, body mass index; IVC, inferior vena cava; SD, standard deviation.
Data presented as mean (SD).
Clinical characteristics of patients in our cohort (n = 19).
| ID | Pathology | PUTH-RTGrade | Mayo | Gender | Age | BMI (kg/m2) | Symptoms | Side | Diameter(cm) | ASAGrade | cN stage | cMstage | Combined thrombi | ThrombusLength(cm) | ThrombusWidth(cm) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ccRCC (metastasis) | PUTH-RT 4 | IV | F | 68 | 23.8 | Systemic | R | 6.3 | 3 | cN1 | M1 | N | 5.5 | 2.7 |
| 2 | Leiomyosarcoma (primary site) | PUTH-RT 2 | II | M | 31 | 20.3 | Local | R | 9.0 | 2 | cN1 | M0 | Y | 4.0 | 2.9 |
| 3 | PHEO | PUTH-RT 3 | II | M | 44 | 21.0 | Local | R | 10.0 | 3 | cN0 | M0 | Y | 4.7 | 3.0 |
| 4 | ACC | PUTH-RT 3 | III | F | 31 | 30.4 | Local | R | 15.0 | 2 | cN0 | M0 | N | 5.0 | 2.1 |
| 5 | hepatocellular carcinoma (metastasis) | PUTH-RT 2 | II | F | 67 | 28.9 | Local | L | 2.8 | 2 | cN1 | M1 | N | 5.9 | 2.7 |
| 6 | Adrenal adenoma | PUTH-RT 1a | 0 | F | 42 | 33.7 | No | L | 7.9 | 2 | cN0 | M0 | N | 1.3 | 1.2 |
| 7 | Ewing Sarcoma (primary site) | PUTH-RT 4 | IV | F | 20 | 18.6 | Local | R | 18.3 | 4 | cN0 | M1 | N | 12.3 | 3.0 |
| 8 | ACC | PUTH-RT 1a | 0 | M | 58 | 24.1 | No | R | 9.4 | 2 | cN0 | M0 | N | 1.5 | 1.0 |
| 9 | Leiomyosarcoma (primary site) | PUTH-RT 3 | III | M | 55 | 18.3 | No | R | 10.7 | 2 | cN0 | M0 | N | 7.5 | 3.2 |
| 10 | Paraganglioma | PUTH-RT 2 | I | M | 16 | 21.0 | Systemic | R | 9.1 | 1 | cN0 | M0 | N | 1.0 | 1.0 |
| 11 | Leiomyosarcoma (primary site) | PUTH-RT 4 | IV | F | 57 | 24.7 | Local | R | 7.1 | 3 | cN1 | M1 | N | 12.0 | 3.9 |
| 12 | Leiomyosarcoma (primary site) | PUTH-RT 3 | II | F | 56 | 28.7 | No | R | 5.8 | 2 | cN0 | M1 | N | 2.8 | 1.6 |
| 13 | ACC | PUTH-RT 2 | II | F | 56 | 36.2 | No | R | 6.5 | 3 | cN0 | M0 | N | 4.0 | 1.0 |
| 14 | PHEO | PUTH-RT 1b | 0 | F | 35 | 21.5 | No | L | 7.4 | 2 | cN0 | M0 | N | 2.3 | 1.3 |
| 15 | ACC | PUTH-RT 2 | II | F | 49 | 21.5 | Local | L | 12.2 | 2 | cN0 | M0 | N | 4.0 | 2.3 |
| 16 | ACC | PUTH-RT 3 | II | F | 69 | 23.1 | Systemic | R | 12.5 | 2 | cN1 | M1 | N | 3.0 | 2.3 |
| 17 | ACC | PUTH-RT 2 | II | F | 54 | 26.0 | No | R | 7.1 | 2 | cN0 | M0 | N | 3.3 | 1.4 |
| 18 | Adrenal neuroblastoma | PUTH-RT 3 | II | M | 38 | 25.1 | Local | L | 10.3 | 2 | cN1 | M0 | N | 7.0 | 3.2 |
| 19 | PHEO | PUTH-RT 1b | 0 | M | 53 | 24.2 | No | L | 8.8 | 2 | cN0 | M0 | N | 2.5 | 2.1 |
ccRCC, clear cell renal cell carcinoma; PHEO, pheochromocytoma; ACC, adrenal cortical carcinoma.
Perioperative data and pathologic result of 19 patients.
| Characteristics | Result |
|---|---|
| Operative time (min), median (IQR) | 342 (153–575) |
| Estimated blood loss (ml), median (IQR) | 1,300 (200–4,500) |
| Patients receiving transfusion, n (%) | 14 (73.7) |
| Postoperative hospital stay (d), mean (SD) | 8 (4–44) |
| ASA grade, n (%) | |
| Grade I | 1 (5.3) |
| Grade II | 13 (68.4) |
| Grade III | 4 (21.1) |
| Grade IV | 1 (5.3) |
| Postoperative complication, n (%) | 5 (26.3) |
| Preoperative serum Cr (μmol/L), median (IQR) | 68 (48–90) |
| Postoperative (1 week) serum Cr (μmol/L), median (IQR) | 66 (41–129) |
| IVC wall invasion, n (%) | 6 (31.6) |
| Presence of bland thrombus, n (%) | 2 (10.5) |
| Lymph node metastasis, n (%) | 3 (15.8) |
IQR, interquartile range; SD, standard deviation; ASA, American Society of Anesthesiologists; Hb, hemoglobin; Cr, creatinine; BUN, blood urea nitrogen; ccRCC, clear cell renal cell carcinoma; IVC, inferior vena cava. Data presented as mean (SD) or median (IQR), unless otherwise noted.
Operation data of patients in our cohort (n = 19).
| ID | Approach | Ipsilateral nephrectomy | Time | Blood loss | RCS transfusion | Plasma transfusion | LN resection | Segmental IVC resection |
|---|---|---|---|---|---|---|---|---|
| 1 | Lap to O | Y | 526 | 2,000 | 800 | 0 | Y | N |
| 2 | O | Y | 288 | 400 | 0 | 0 | N | N |
| 3 | O | N | 486 | 2,700 | 1,600 | 800 | N | N |
| 4 | O | N | 504 | 3,500 | 3,200 | 1,400 | N | N |
| 5 | O | N | 216 | 1,500 | 1,200 | 0 | N | N |
| 6 | Lap | N | 153 | 200 | 0 | 0 | N | N |
| 7 | O | N | 587 | 4,500 | 2,800 | 2,200 | N | N |
| 8 | Lap | N | 193 | 200 | 0 | 0 | N | N |
| 9 | O | Y | 256 | 800 | 800 | 0 | N | N |
| 10 | O | Y | 329 | 1,000 | 1,200 | 400 | N | N |
| 11 | O | N | 297 | 2,000 | 2,800 | 800 | N | Y |
| 12 | O | N | 377 | 900 | 600 | 0 | N | N |
| 13 | Lap | N | 335 | 800 | 400 | 0 | N | N |
| 14 | Lap | N | 217 | 100 | 0 | 0 | Y | N |
| 15 | O | Y | 440 | 2,000 | 1,600 | 400 | Y | N |
| 16 | O | N | 355 | 3,500 | 2,800 | 1,400 | Y | N |
| 17 | O | N | 261 | 900 | 0 | 0 | N | N |
| 18 | O | Y | 575 | 3300 | 2800 | 1600 | Y | N |
| 19 | Lap | N | 429 | 1600 | 800 | 400 | N | N |
Lap to O, laparoscopic approach to open approach; O, open approach; Lap, laparoscopic approach.
Postoperative data of patients in our cohort (n = 19).
| ID | P.O.stay | Pre-Cr (μmol/L) | Post-Cr (μmol/L) | pN stage | IVC invasion | Complication | Follow-up | Status | Recurrence | P.O. treatment |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 8 | 54 | 53 | Y | N | Infection | 69.0 | Alive | Lung | Sunitinib |
| 2 | 8 | 88 | 129 | N | Y | – | 49.0 | Alive | No | – |
| 3 | 10 | 81 | 66 | N | Y | Anemia | 41.0 | Alive | No | – |
| 4 | 9 | 63 | 66 | N | N | Anemia | 10.0 | Alive | Liver metastasis | Radiotherapy |
| 5 | 8 | 67 | 87 | N | N.A | – | 7.0 | Alive | No | – |
| 6 | 4 | 48 | 54 | N | N | – | 3.0 | Alive | Lymph node | Chemotherapy |
| 7 | 44 | 67 | 118 | N | N | Anemia | 21.0 | Alive | No | – |
| 8 | 5 | 65 | 57 | N | N | – | 5.0 | Alive | No | – |
| 9 | 6 | 74 | 93 | N | N | – | 27.0 | Alive | No | – |
| 10 | 8 | 90 | 81 | N | Y | – | 26.0 | Alive | No | – |
| 11 | 16 | 78 | 64 | N | Y | – | 7.0 | Dead | No | – |
| 12 | 13 | 68 | 41 | N | N | P.E. | 24.0 | Alive | No | – |
| 13 | 8 | 54 | 58 | N | N | – | 7.0 | Alive | Multiple organ | – |
| 14 | 5 | 60 | 87 | N | N | – | 22.0 | Alive | No | – |
| 15 | 9 | 56 | 45 | N | Y | – | 16.0 | Alive | – | – |
| 16 | 10 | 71 | 50 | N | N | – | 11.0 | Dead | Liver | – |
| 17 | 5 | 75 | 88 | N | N | – | 14.0 | Dead | Retroperitoneal | Immnotherapy |
| 18 | 12 | 90 | 103 | N | Y | – | 9.0 | Alive | Diaphragmatic | Erlotinib |
| 19 | 4 | 71 | 93 | N | N | – | 3.0 | Alive | No | – |
P.O., postoperative; P.E., pulmonary embolism.